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A B S T R A C T
Background
Irritable bowel syndrome (IBS) is a common, chronic disorder that leads to decreased health-related quality of life and work productivity.
A previous version of this review was not able to draw firm conclusions about the effectiveness of homeopathic treatment for IBS and
recommended that further high quality RCTs were conducted to explore the clinical and cost effectiveness of homeopathic treatment
for IBS. Two types of homeopathic treatment were evaluated in this systematic review: 1. Clinical homeopathy where a specific remedy
is prescribed for a specific condition; 2. Individualised homeopathic treatment, where a homeopathic remedy based on a person’s
individual symptoms is prescribed after a detailed consultation.
Objectives
To assess the effectiveness and safety of homeopathic treatment for IBS.
Search methods
For this update we searched MEDLINE, CENTRAL, Embase, Cumulative Index to Nursing and Allied Health Literature (CINAHL),
Allied and Complementary Medicine Database (AMED), the Cochrane IBD Group Specialised Register and trials registers from
inception to 31 August 2018.
Selection criteria
Randomised controlled trials (RCTs), cohort and case-control studies that compared homeopathic treatment with placebo, other control
treatments, or usual care, in adults with IBS were considered for inclusion.
Data collection and analysis
Two authors independently assessed the risk of bias and extracted data. The primary outcome was global improvement in IBS as
measured by an IBS symptom severity score. Secondary outcomes included quality of life, abdominal pain, stool frequency, stool
consistency, and adverse events. The overall certainty of the evidence supporting the primary and secondary outcomes was assessed
using the GRADE criteria. We used the Cochrane risk of bias tool to assess risk of bias. We calculated the mean difference (MD) and
95% confidence interval (CI) for continuous outcomes and the risk ratio (RR) and 95% CI for dichotomous outcomes.
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Main results
Four RCTs (307 participants) were included. Two studies compared clinical homeopathy (homeopathic remedy, asafoetida or asafoetida
plus nux vomica) to placebo for IBS with constipation (IBS-C). One study compared individualised homeopathic treatment (consul-
tation plus remedy) to usual care for the treatment of IBS in female patients. One study was a three armed RCT comparing individu-
alised homeopathic treatment to supportive listening or usual care. The risk of bias in three studies (the two studies assessing clinical
homeopathy and the study comparing individualised homeopathic treatment to usual care) was unclear on most criteria and high for
selective reporting in one of the clinical homeopathy studies. The three armed study comparing individualised homeopathic treatment
to usual care and supportive listening was at low risk of bias in four of the domains and high risk of bias in two (performance bias and
detection bias).
A meta-analysis of the studies assessing clinical homeopathy, (171 participants with IBS-C) was conducted. At short-term follow-up of
two weeks, global improvement in symptoms was experienced by 73% (46/63) of asafoetida participants compared to 45% (30/66) of
placebo participants (RR 1.61, 95% CI 1.18 to 2.18; 2 studies, very low certainty evidence). In the other clinical homeopathy study at
two weeks, 68% (13/19) of those in the asafoetida plus nux vomica arm and 52% (12/23) of those in the placebo arm experienced a
global improvement in symptoms (RR 1.31, 95% CI 0.80 to 2.15; very low certainty evidence). In the study comparing individualised
homeopathic treatment to usual care (N = 20), the mean global improvement score (feeling unwell) at 12 weeks was 1.44 + 4.55 (n =
9) in the individualised homeopathic treatment arm compared to 1.41 + 1.97 (n=11) in the usual care arm (MD 0.03; 95% CI -3.16
to 3.22; very low certainty evidence).
In the study comparing individualised homeopathic treatment to usual care, the mean IBS symptom severity score at 6 months was
210.44 + 112.4 (n = 16) in the individualised homeopathic treatment arm compared to 237.3 + 110.22 (n = 60) in the usual care arm
(MD -26.86, 95% CI -88.59 to 34.87; low certainty evidence). The mean quality of life score (EQ-5D) at 6 months in homeopathy
participants was 69.07 (SD 17.35) compared to 63.41 (SD 23.31) in usual care participants (MD 5.66, 95% CI -4.69 to 16.01; low
certainty evidence).
For In the study comparing individualised homeopathic treatment to supportive listening, the mean IBS symptom severity score at
6 months was 210.44 + 112.4 (n = 16) in the individualised homeopathic treatment arm compared to 262 + 120.72 (n = 18) in the
supportive listening arm (MD -51.56, 95% CI -129.94 to 26.82; very low certainty evidence). The mean quality of life score at 6
months in homeopathy participants was 69.07 (SD 17.35) compared to 63.09 (SD 24.38) in supportive listening participants (MD
5.98, 95% CI -8.13 to 20.09; very low certainty evidence).
None of the included studies reported on abdominal pain, stool frequency, stool consistency, or adverse events.
Authors’ conclusions
The results for the outcomes assessed in this review are uncertain. Thus no firm conclusions regarding the effectiveness and safety of
homeopathy for the treatment of IBS can be drawn. Further high quality, adequately powered RCTs are required to assess the efficacy
and safety of clinical and individualised homeopathy for IBS compared to placebo or usual care.
P L A I N L A N G U A G E S U M M A R Y
Homeopathy for treatment of irritable bowel syndrome
What is irritable bowel syndrome?
Irritable bowel syndrome (IBS) is a common chronic disorder where a person experiences the following symptoms: abdominal pain,
discomfort, bloating, constipation or diarrhoea or both. It is difficult to treat because different people experience different symptoms.
Some people experience constipation as the main symptom, this form of IBS is known as IBS-C, while others experience diarrhoea
as the main symptom. This form of IBS is known as IBS-D. Others experience both constipation and diarrhoea, this form of IBS is
known as IBS-M where the M stands for mixed. Currently there is no agreement on the best form of treatment for IBS.This means
that it is important to evaluate the effectiveness and safety of treatments, including homeopathic treatment, which some IBS sufferers
use.
What is homeopathy?
There are different types of homeopathy. Clinical homeopathy matches a ’remedy’ to a specific condition, such as IBS and everybody
who has that condition would be given the same remedy. Individualised homeopathy involves a series of in-depth consultations to
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assess symptoms and other issues that may affect the patient. Following an in-depth consultation the homeopath will select the most
appropriate remedy based on the persons’ individual symptoms. Individualised homeopathy includes both a consultation and a remedy,
whereas clinical homeopathy consists of a remedy without the in-depth consultation.
What did the researchers investigate?
The researchers investigated whether homeopathic treatment led to the improvement of the symptoms of IBS in people with IBS. The
researchers
What did the researchers find?
Four randomised controlled trials (RCTs) with 307 participants with IBS were included. Two RCTs (129 participants) compared a
homeopathic remedy (asafoetida and asafoetida plus nux vomica) to a placebo remedy for the treatment of people with IBS-C. One
study (23 participants) compared individualised homeopathic treatment to usual care in female patients diagnosed with IBS. One study
(94 participants) was a three armed study comparing individualised homeopathic treatment plus usual care, supportive listening plus
usual care and usual care.
The four trials tested the effects of homeopathic treatment on the severity of IBS symptoms. No conclusions can be drawn from the
RCT comparing individualised homeopathic treatment to usual care due to the small number of participants and the low quality of
reporting in this trial. This study was carried out in 1990 and usual care for IBS may have changed since then making the results
difficult to compare to current treatments.
No conclusions can be drawn from the three armed study comparing individualised homeopathic treatment plus usual care, supportive
listening plus usual care and usual care due to the small number of participants in the homeopathic treatment arm (n=16).
The results of two small studies were combined (129 participants) and this suggested that there may be a possible benefit for clinical
homeopathy, using the remedy asafoetida, over placebo for patients with IBS-C at a short-term follow-up of two weeks. However both
of the studies were carried out in the 1970s when the reporting of trials was not as comprehensive as it is now and we are very uncertain
about these results and cannot suggest a possible benefit for clinical homeopathy.
Conclusions
The results for the outcomes assessed in this review are uncertain. Thus no firm conclusions regarding the effectiveness and safety of
homeopathy for the treatment of IBS can be drawn. Further high quality RCTs enrolling larger numbers of patients are required to
assess the effectiveness and safety of clinical and individualised homeopathy for IBS.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Homeopathy versus placebo for the treatment of irritable bowel syndrome
Patient or population: pat ients with irritable bowel syndrome
Settings: outpat ients
Intervention: homeopathy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with homeopathy
Global improvement
(Asafoetida subgroup)
Follow-up: 2 weeks
455 per 1000 732 per 1000
(536 to 991)
RR 1.61
(1.18 to 2.18)
129
(2 studies)
⊕©©©
very low1,2,3
Global improvement de-
f ined as self improve-
ment on a 3 point Likert
scale
Global improvement
(Asafoetida + nux vom
subgroup)
Follow-up: 2 weeks
522 per 1000 683 per 1000
(417 to 1000)
RR 1.31
(0.8 to 2.15)
42
(1 study)
⊕©©©
very low1,3,4
Global improvement de-
f ined as self improve-
ment on a 3 point Likert
scale
Quality of life Not reported This outcome was not
reported
Abdominal pain Not reported This outcome was not
reported
Stool frequency Not reported This outcome was not
reported
Stool consistency Not reported This outcome was not
reported
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Adverse events Not reported This outcome was not
reported
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded one level due to high risk of bias
2 Downgraded one level due to sparse data (76 events)
3 Downgraded one level due to the endpoint t ime (2 weeks). Given the long term nature of IBS it is not clear how useful a two
week outcome is for pat ients’ and clinicians’ decision making.
4 Downgraded two levels due to very sparse data ( 25 events)
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B A C K G R O U N D
Description of the condition
Irritable bowel syndrome (IBS) is a common, chronic disorder
that affects 10 to 22% of the population in the UK (Williams
2007). The economic costs of IBS in primary care in the UK
are estimated to be over GBP 200 million per year (Akehurst
2002). It is difficult to treat because no single cause has been
identified. Treatment is directed at controlling symptoms, using
pharmacological and non-pharmacological approaches (Ruepert
2011; Spiller 2007; Zijdenbos 2009).
IBS is characterised by recurrent symptoms (i.e. abdominal pain
or discomfort, bloating, constipation, or diarrhoea) that indicate a
dysfunctional gastrointestinal tract rather than an organic change
or specific diagnosis. It has an uncertain prognosis for recov-
ery (Mearin 2006). Such patients have a plethora of non-colonic
symptoms such as back pain, urinary frequency, and chronic fa-
tigue which can lead to the patient being referred to the wrong
specialty and having inappropriate investigations and even surgery.
This can lower quality of life (Agrawal 2006; Longstreth 2007).
In addition, sleep disturbance and depressed mood are common
in IBS patients.
Diagnosis of IBS can be made using the Rome IV criteria
(Drossman 2016), although this is largely a research tool used to
allow common reporting standards of symptoms in trials and other
research populations. In clinical practice the diagnosis of IBS is
largely based on symptoms and should be positive rather than by
exclusion, although the presence of alarm symptoms (e.g. blood
in stool, weight loss or family history) should prompt further in-
vestigations (Spiller 2007). IBS can be characterised into the fol-
lowing subtypes: IBS with constipation, IBS with diarrhoea, IBS
with mixed bowel habits and unspecified.
Usual care for IBS commonly includes advice on lifestyle, includ-
ing diet and stress reduction, possibly combined with medication.
There are a number of different medications used to help treat IBS:
antispasmodic medicines, which help to reduce abdominal pain
and cramping; laxatives, which help to treat the symptoms of con-
stipation; anti-motility medicines, which help to treat the symp-
toms of diarrhoea, and neuropathic modulators such as tricyclic
antidepressants, which were originally designed to treat depression,
but also help to reduce the feeling of abdominal pain and cramp-
ing. Alternative treatments such as hypnotherapy, psychotherapy
and acupuncture have been tried and have a place in selected
patients (Agrawal 2006,McPherson 2012). However these treat-
ments have limited availability and are expensive and labour in-
tensive. Despite much research into both psychological and phar-
macological treatments for irritable bowel syndrome no consensus
exists on its optimal treatment (Ruepert 2011; Zijdenbos 2009).
Description of the intervention
Homeopathy is a popular, albeit controversial form of complemen-
tary and alternative medicine. A UK survey has shown that 1.9%
of the population consulted a homeopath in the 12 months prior
to the survey and 8.6% had bought an over-the-counter homeo-
pathic remedy (Thomas 2001). Homeopathy is based on treating
patients with remedies prepared from substances that have been
highly diluted and succussed (shaken). It was first developed by
Samuel Hahnemann in the eighteenth century in Germany and
works on the principle of “like cures like” whereby a substance
that would cause symptoms in a healthy person cures those same
symptoms in illness.
Homeopathic treatment varies among different practitioners and
four main types can be identified (Linde 1997):
• Individualised (or classical) homeopathy, the type most
commonly practised in the UK, involves a consultation followed
by the prescription of a homeopathic medicine individualised to
the patient;
• Clinical homeopathy, where the same homeopathic
medicine is used for a group of patients all presenting with the
same clinical condition (e.g. lycopodium for IBS, arnica for
bruising);
• Complex homeopathy, where a number of different
homeopathic medicines are given either in a fixed combination
or concurrently; and
• Isopathy, where the homeopathic medicine is based on the
substance which has led to the problem (e.g. grass pollen for hay
fever).
Homeopathic medicines when prescribed by trained professionals
are generally regarded as safe (Dantas 2000).
How the intervention might work
Homeopathy is based on the ‘law of similars’ i.e. a substance which
causes symptoms in a healthy individual can be used to treat sim-
ilar symptoms in a diseased person (Vithoulkas 1980).There is
significant debate regarding the scientific basis for homeopathy
amongst healthcare practitioners, scientists, politicians and policy
makers and the mechanism by which homeopathic remedies may
work is not completely understood.
The manufacture of homeopathic medicines involves serial dilu-
tion alternating with violent agitation (i.e. ‘succussion’). The com-
bination of these two processes is referred to as ‘potentisation’ or ‘se-
quential kinetic activation’ (Gariboldi 2009). Many homeopathic
medicines are diluted beyond Avogadro’s number and therefore
fall under the classification of ultra-high dilutions (UHDs). Avo-
gadro’s number is the number of molecules in a mole of a sub-
stance, approximately 6.0225 × 1023, which means that a sample
diluted beyond 1024 would have reached a stage where it is very
unlikely that there is even a single molecule of the original sub-
stance present. The biological efficacy of UHDs may be depen-
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dent on sequential kinetic activation (Gariboldi 2009), but the
mechanism by which sequential kinetic activation enables a UHD
to be biologically active is unknown. A common theory is that it
involves stable water structures, created by interactions between
molecules of the biological material and the water it is dissolved
in, allowing the water to retain information about the biological
material (Montagnier 2009).
Why it is important to do this review
This review is an update of a previously published Cochrane review
on homeopathy for irritable bowel syndrome (Peckham 2012).
The original review marked a small step forward in establishing
whether or not homeopathy is an effective treatment for IBS; how-
ever due to the small number of studies, age of the studies and
methodological limitations the original review provided only lim-
ited information. This updated review is timely not only because
of the passage of time but also given the continued lack of effective
treatments for IBS and the sustained interest in homeopathy as a
potential treatment option. Lower gastrointestinal tract disorders
account for one in 20 of all general practice consultations in the
UK (Thompson 2000). In addition, gastroenterology problems
are the fourth most common referral to National Health Service
(NHS) homeopathic hospitals (Spence 2005) and one of the eight
most common conditions treated by NHS homeopaths in gen-
eral practice (Mathie 2006). The frequency with which people
with IBS consult homeopaths may be some indication of the value
which they place on the homeopathic approach. Homeopathic
treatment may offer a treatment strategy for patients with IBS, but
at present it is not clear if it offers any benefit.
O B J E C T I V E S
The objective of this systematic review is to assess the effectiveness
and safety of homeopathic treatment for IBS.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) comparing homeopathic
treatment with placebo or active comparators were considered for
inclusion regardless of blinding method, publication status and
language of publication. Quasi randomised studies were also con-
sidered for inclusion, where allocation was achieved by ’quasi-ran-
dom’ methods such as alternation between treatment arms, year of
birth, month entered into study. Cohort and case-control studies
were also considered for inclusion.
Types of participants
All trials of patients with a diagnosis of IBS were eligible for in-
clusion in this review regardless of age, gender, race, educational
status or duration of IBS. Trials which included IBS patients in
whom 10% or more had unstable psychiatric disorders, ulcerative
colitis, Crohn’s disease, bowel cancer and pregnant and breastfeed-
ing women were excluded from this review.
Types of interventions
Trials were included if one of the groups in the trial received any
type of homeopathic treatment involving the delivery of a home-
opathic remedy (either by a homeopath following a consultation
or studies where a homeopathic remedy was delivered without a
consultation) and the other received placebo, an active comparator
treatment, or no treatment.
Types of outcome measures
All trials that included any one of the following outcome measures
were included in the review.
Primary outcomes
The primary outcome was global improvement of symptoms (pa-
tient-reported or clinician-evaluated or both) as measured by a
global IBS symptom score (e.g. IBS Severity Scoring System (IBS-
SSS), Adequate Relief Measure, GI Symptom Rating Scale, Func-
tional Bowel Disorder Severity Index or IBS Symptom Question-
naire).
Secondary outcomes
Secondary outcomes included:
• Quality of life as measured by validated quality of life
measure e.g. EQ5D, SF36, IBS Quality of Life Measure, IBS
Quality of Life Questionnaire, Functional Digestive Disorder
Quality of Life Questionnaire, IBS Health Related Quality of
Life Questionnaire;
• Abdominal pain, discomfort and distension;
• Stool frequency, bowel transit time;
• Stool consistency; and
• Adverse events.
Search methods for identification of studies
Electronic searches
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The following electronic databases were searched from inception
to 31 August 2018:
The Cochrane Central Register of Controlled Trials (CENTRAL)
on the Cochrane Library, Ovid MEDLINE, EMBASE, the Cumu-
lative Index to Nursing and Allied Health Literature (CINAHL)
and the Allied and Complementary Medicine Database (AMED).
The Cochrane IBD/FBD Group Specialised Register, Clinical tri-
als.gov and the WHO International Clinical Trials Registry Plat-
form (ICTRP) http://www.who.int/ictrp/en/ were also searched.
Searching other resources
1. Reference searching
The reference lists for all identified studies were inspected for ad-
ditional studies.
2. Personal contact
The first author of each included study was contacted for infor-
mation regarding unpublished trials.
Data collection and analysis
Selection of studies
Two authors (EJP and SB) independently reviewed the titles and
abstracts of the studies identified by the literature search. Included
studies were assessed against the predefined inclusion criteria.
Data extraction and management
Two authors (EP and SB) independently extracted data from the
included studies. Authors were contacted to clarify any unclear
data. EP who is an author of one of the included studies was not
involved in the data extraction or assessment of the risk of bias for
the study that she was involved in the conduct of, GT extracted
the data for this study.
Assessment of risk of bias in included studies
Two authors (SB and GT) independently assessed the method-
ological quality of included randomised trials using the Cochrane
risk of bias tool (Higgins 2011). The following items were assessed:
• sequence generation (i.e. was allocation sequence
adequately generated?);
• allocation sequence concealment (i.e. was allocation
adequately concealed?);
• blinding (i.e. was knowledge of the allocated interventions
adequately prevented during the study?);
• incomplete outcome data (i.e. were incomplete outcome
data adequately addressed?);
• selective outcome reporting (i.e. are reports of the study free
of suggestion of selective outcome reporting?); and
• other potential sources of bias (i.e. was the study apparently
free of other problems that could lead to a high risk of bias e.g.
baseline imbalances, evidence of carry-over in cross-over trials,
comparability of groups in cluster trials).
It was intended that, based on these criteria the studies would be
subdivided into three categories:
1. Low risk of bias i.e. all quality criteria met;
2. Medium risk of bias i.e. one or more of the quality criteria partly
met; and
3. High risk of bias i.e. one or more of the quality criteria not met.
It was intended that the quality of quasi-randomised trials, non-
randomised trials, cohort and case control studies would be as-
sessed using a quality instrument designed for assessing the quality
of non-randomised studies (Downs 1998).
Using the GRADE (Grading of Recommendations Assess-
ment, Development and Evaluation) approach (Atkins 2004,
Schünemann 2011), we will assess the overall quality of the evi-
dence supporting the following outcomes: global improvement of
symptoms, quality of life, improvement in abdominal pain, stool
frequency, stool consistency and adverse events. The summary of
the evidence will be presented in a ’Summary of findings’ table,
which will provide key information about the best estimate of the
magnitude of the effect for each relevant comparison, and the rat-
ing of the overall confidence in effect estimates for each outcome.
The GRADEpro Guideline Development Tool will be used to cre-
ate the ’Summary of findings’ table.
Measures of treatment effect
Review Manager (RevMan 5.3.5) was used to analyse the data. For
continuous outcomes the mean difference (MD) with 95% con-
fidence interval (95% CI) was calculated. For each dichotomous
outcome the risk ratio (RR) with 95% CI was calculated.
Unit of analysis issues
We did not anticipate any unit of analysis issues arising from clus-
ter randomisation. In the case of multiple intervention groups
each intervention group was analysed separately against the con-
trol group and the sample size for the control group was divided
proportionately across each intervention group. We noted that if
the results were reported at multiple time points in the studies,
each outcome would be analysed at pre-defined periods of follow-
up in separate meta-analyses. Time points would be grouped as
follows: less than three months, three months to one year, longer
than one year. These time points were chosen as representing time
frames in which a difference in the likelihood of responding could
be expected.
Dealing with missing data
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We intended to analyse data using the intention to treat (ITT)
principle and sensitivity analyses were to be undertaken as appro-
priate (e.g. ITT versus available case, and study quality). However,
data were analysed on an available case basis as the included studies
did not provide enough detail to allow for an ITT analysis.
Assessment of heterogeneity
Statistical heterogeneity was assessed using the Chi² test and the
I² statistic. If heterogeneity existed between studies (I² ≥ 50%)
for the primary outcome, reasons for the heterogeneity would be
explored. Clinical heterogeneity would be assessed through the
description of the setting and homeopathic approach used in each
study.
Assessment of reporting biases
In the protocol we noted that if more than 10 studies were iden-
tified for inclusion in this review, funnel plots would be used to
assess publication biases.
Data synthesis
Data from individual trials were combined by meta-analysis if
the interventions, outcomes and patient groups were sufficiently
similar (determined by consensus). For continuous data the MD
with 95% CI was calculated where the same scales have been used.
Where studies were deemed sufficiently similar but different scales
have been used the standardised mean difference (SMD) would
be used to combine data. For dichotomous outcomes the pooled
RR and 95% CI were calculated.
In the protocol we specified that data would not be pooled for
meta-analysis if a high degree of heterogeneity (I² > 75%) was
detected. A fixed-effect model would be used to pool data in the
absence of heterogeneity. An I² ≥ 50% is considered to represent
moderate heterogeneity and in such cases (I² 50 to 75%) a random-
effects model would be used for pooling the data.
Subgroup analysis and investigation of heterogeneity
Subgroup analysis was planned between studies that prospectively
identified IBS patients using ROME III criteria versus studies that
did not use ROME III criteria to prospectively identify IBS pa-
tients. In the protocol we also noted that if data were reported
separately for the different forms of IBS then a subgroup analysis
comparing the different forms would be carried out. A subgroup
analysis was also planned for quasi and true randomisation, differ-
ent comparators (e.g. no treatment, usual care, placebo, or other
active treatment) and different homeopathy interventions (e.g. in-
dividualised or clinical homeopathy).
Sensitivity analysis
In the protocol we noted that if a sufficient number of trials were
identified a sensitivity analysis would be carried out by study qual-
ity to determine if the results of the primary analysis change ac-
cording to which trials are incorporated into the analysis.
R E S U L T S
Description of studies
See Characteristics of included studies and Characteristics of
excluded studies and Characteristics of ongoing studies.
Results of the search
Figure 1 shows details of the search and selection process. From
citations initially identified, full text sources were examined (after
removal of duplicates and assessment of abstract), studies were ex-
cluded for various reasons (listed in the excluded studies table) and
four studies plus two secondary publications from two included
studies were included in the review (Owen 1990; Peckham 2014;
Rahlfs 1976; Rahlfs 1979). Two studies were included in quan-
titative synthesis (Rahlfs 1976; Rahlfs 1979). No cohort or case-
control studies were identified.
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Figure 1. Study flow diagram.
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Included studies
Four studies with a total of 307 participants were included
(Owen 1990; Peckham 2014; Rahlfs 1976; Rahlfs 1979). See
Characteristics of included studies. Owen 1990 and Peckham
2014 were conducted in the UK and published in English. Rahlfs
1976 and Rahlfs 1979 were conducted in the former Federal Re-
public of Germany and published in German and were trans-
lated from German into English. Rahlfs 1976, was a three arm
trial comparing asafoetida against asafoetida + nux vomica, against
placebo, whereas Rahlfs 1979 compared asafoetida versus placebo
(the participants in the two trials are independent). The authors
noted that Rahlfs 1976 failed to recruit its target number of par-
ticipants, hence the (simplified) trial being re-run. There were 23
participants in Owen 1990, 72 participants in Rahlfs 1976, 119
participants in Rahlfs 1979 and 94 participants in Peckham 2014.
All included studies were published as full articles.
Owen 1990 compared individualised homeopathic treatment,
which involved a homeopathic consultation and an individualised
homeopathic remedy, to usual care which consisted of high doses
of dicyclomine hydrochloride, faecal bulking agents and diet sheets
asking the patient to take a high fibre diet. This study differs from
other pragmatic trials of individualised homeopathic treatment,
where the more common approach has been to compare individ-
ualised homeopathic treatment plus usual care to usual care alone.
In Owen 1990 participants were asked to rate how unwell they
felt before and after treatment, exact details of how this was scored
are not given. Although Owen 1990 did not include a global mea-
surement of IBS as one of the outcomes, we considered the rating
of how unwell patients felt to provide a global measurement of
the patients’ health. The other outcome measures in Owen 1990
involved the patients choosing their own top four worst symptoms
and grading these on a visual analogue scale, it was not specified
that these symptoms had to be related to IBS, and details of the
symptoms patients chose were not reported are not given, hence
this outcome measure was not included in this review.
Peckham 2014 was a three armed trial that compared individu-
alised homeopathic treatment plus usual care to supportive listen-
ing plus usual care to usual care alone. Unequal randomisation
was used in Peckham 2014 with 16 participants allocated to indi-
vidualised homeopathic treatment, 18 to supportive listening and
60 to usual care. Individualised homeopathic treatment involved
a homeopathic consultation and an individualised homeopathic
remedy. Supportive listening aimed to control for the time and
attention given to the patient in the individualised homeopathic
treatment arm and consisted of the same number of sessions of the
same duration as the homeopathic consultation. In both the indi-
vidualised homeopathic treatment and supportive listening arms
patients were offered five one hour sessions with a homeopath or
counsellor respectively. The primary outcome measure in Peckham
2014 was change in IBS-SSS at 6 months.
None of the included studies reported on adverse events as an
outcome.
Excluded studies
The Characteristics of excluded studies table, describes the charac-
teristics of the 32 excluded studies along with the reason for their
exclusion.
Ongoing studies
No ongoing studies were identified.
Risk of bias in included studies
The risk of bias in the included studies for each domain are dis-
cussed below. See results of the risk of bias analysis are summarized
in Figure 2.
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Figure 2. Methodological quality summary: review authors’ judgments about each methodological quality
item for each included study.
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Allocation
Owen 1990, Rahlfs 1976, Rahlfs 1979 and Peckham 2014 were
described as RCTs. Owen 1990 reported that the participants were
stratified and randomised into one of two treatment groups. How-
ever, no details were given about the stratification or how randomi-
sation sequence was generated. Rahlfs 1976 reported that a chance
code was used for randomisation, although what this entailed and
how it was implemented was not described. Rahlfs 1979 did not
report any information regarding the method of generation of the
randomisation code. Peckham 2014 reported that the random se-
quence was generated by shuffling of sealed opaque envelopes con-
taining the allocation and was reported as being of low risk of bias
for allocation concealment. Rahlfs 1976 and Rahlfs 1979 provided
medication in sequentially numbered drug containers and were
rated as low risk for allocation concealment. Owen 1990 did not
describe the procedure used for allocation concealment and was
rated as unclear for this item.
Blinding
Participants and physicians were not blinded to treatment alloca-
tion in the Owen 1990 and Peckham 2014 studies as it was not
possible to design a study where participants were not aware of
their receiving an individualised homeopathic consultation, sup-
portive listening or usual care. Owen 1990 did not report whether
other key study personnel were blinded, or whether outcome as-
sessment was carried out blind. In Peckham 2014 outcomes were
participant reported and due to participants being aware of their
allocation outcomes were at high risk of bias. In Rahlfs 1976 and
Rahlfs 1979 the study participants and the doctors who recruited
the participants were blinded to allocation by the use of an iden-
tical placebo. In Rahlfs 1979, the participant blinding was well
described. Rahlfs 1976 and Rahlfs 1979 did not report whether
other key study personnel were blinded, or if outcome assessment
was carried out blind.
Incomplete outcome data
The number of patient withdrawals was reported for Owen 1990,
Rahlfs 1976, Rahlfs 1979 and Peckham 2014. Although Owen
1990 reported the number of withdrawals and the arm from which
the patients withdrew, the reasons for withdrawal were not re-
ported. In Peckham 2014 the reasons for withdrawal were reported
and a comparison of baseline data was made between those who
had missing data and those who did not, this indicated that there
was a relationship between age, employment status and missing
data, hence employment status and age were included in the AN-
COVA model for the primary outcome. Rahlfs 1976 did not re-
port which arms that patients withdrew from and therefore it was
not clear whether there may be attrition bias in this trial. Rahlfs
1979 reported the number of withdrawals from each treatment
group and the reasons for withdrawal. Whilst dropouts appear
to be comparable in terms of number and reason for withdrawal
across both arms of this study (Rahlfs 1979), it should be remem-
bered that any dropout threatens group comparability at base-
line as random allocation seeks to distribute both known and un-
known characteristics across groups, and dropouts may differ for
unknown characteristics that cannot be measured.
Selective reporting
Due to insufficient reporting in Owen 1990 and Rahlfs 1976 both
studies were rated as unclear for the item on selective reporting.
Rahlfs 1979 was deemed to be at a high risk of bias due to selec-
tive reporting because of evidence of selective choice of data for
an outcome. Some participants were excluded from the outcome
analyses for not meeting the inclusion criteria while other partici-
pants who did not meet the inclusion criteria in terms of age were
included in the analyses. Peckham 2014 was deemed to be at low
risk of bias for selective reporting due to all the outcomes being
reported in the protocol paper being presented in the main paper.
Other potential sources of bias
Due to the low quality of reporting in Owen 1990, Rahlfs 1976
and Rahlfs 1979, the potential for other sources of bias in these
studies could not be assessed. No other potential sources of bias
were identified in Peckham 2014, however it cannot be certain
that there were no other sources of bias so this has been marked
as unclear.
Effects of interventions
See: Summary of findings for the main comparison
Homeopathy versus placebo; Summary of findings 2
Homeopathy versus usual care; Summary of findings 3
Homeopathy plus usual care versus usual care; Summary of
findings 4 Homeopathy plus usual care versus supportive listening
plus usual care
Clinical homeopathic remedy versus placebo remedy
Rahlfs 1976 and Rahlfs 1979 assessed global improvement in IBS
at two weeks as an outcome measure. For this outcome patients
were asked to measure their improvement on a three-point scale
(Rahlfs 1976) and a four-point scale (Rahlfs 1979). For the Rahlfs
1976 study participants were asked to rate whether they were not
or negligibly improved, more than half improved or free of symp-
toms. Participants in the Rahlfs 1979 study were asked to rate
whether they were worse, not or negligibly improved, more than
half improved or free of symptoms. For the purposes of this review,
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we dichotomised these scales into two categories: those who had
improved (more than half improved or free of symptoms) versus
those who had not improved (those who were worse, or not or
negligibly improved).
At short term follow up of two weeks, a pooled analysis (129 par-
ticipants) indicated that there may be a benefit of the homeopathic
treatment asafoetida over placebo. At short-term follow up of two
weeks, the RR for global improvement in symptoms for asafoetida
versus placebo was 1.61 (95% CI 1.18 to 2.18; very low certainty
evidence). Little heterogeneity was detected for this comparison
(I² = 18%). For the study that compared homeopathic remedy
(asafoetida plus nux vomica) to placebo the RR was 1.31 (95%
CI 0.80 to 2.15; very low certainty evidence).
Homeopathic treatment versus usual care
In Owen 1990 participants (N = 20) were asked to rate how unwell
they felt before and after treatment. The effect of individualised
homeopathic treatment was uncertain. The mean global improve-
ment score (i.e. how unwell the participants felt - a lower score
indicates feeling more unwell) in the individualised homeopathic
treatment arm was 1.44 (SD 4.55) compared to 1.41 (SD 1.97)
in the usual care arm (MD 0.03, 95% CI -3.16 to 3.22; very low
certainty evidence).
Homeopathic treatment plus usual care versus usual care
In Peckham 2014 participants were asked to complete the IBS-SSS
at baseline and at 6 months. The effect of individualised homeo-
pathic treatment at 6 months was uncertain. In the individualised
homeopathic treatment plus usual care arm the mean IBS-SSS
score was 210.44 (SD 112.4) compared to 237.30 (SD 110.22)
in the usual care arm (MD -26.86, 95% CI -88.59 to 34.87; low
certainty evidence). A lower score indicates less severity of symp-
toms.
Homeopathic treatment plus usual care versus supportive lis-
tening plus usual care
In Peckham 2014 participants were asked to complete the IBS-SSS
at baseline and at 6 months. The effect of homeopathic treatment
compared to supportive listening was uncertain. At six months the
mean IBS-SSS score in the homeopathic treatment plus usual care
arm was 210.44 (SD 112.4) compared to 262.00 (SD 120.72) in
the supportive listening plus usual care arm (MD -51.56, 95%
CI -129.94 to 26.82; very low certainty evidence). A lower score
indicates less severity of symptoms.
Secondary outcome measures
The secondary outcomes quality of life, abdominal pain, stool fre-
quency, stool consistency and adverse events were not reported on
in Rahlfs 1976, Rahlfs 1979 or Owen 1990. Quality of life using
the EQ-5D was reported on in Peckham 2014. The effect of in-
dividualised homeopathic treatment on quality of life was uncer-
tain. In the homeopathic treatment arm the mean EQ-5D visual
analogue score (VAS) at six months was 69.07 (SD 17.35) com-
pared to 63.41 (SD 23.31) in the usual care arm (MD 5.66, 95%
CI -4.69 to 16.01; low certainty evidence). In the homeopathic
treatment arm the mean EQ-5D score at six months was 69.07
(SD 17.35) compared to 63.09 (SD 24.38) in the supportive lis-
tening arm (MD 5.98, 95% CI -8.13 to 20.09; very low certainty
evidence). A lower score indicates a worse quality of life.
Pooling of results
Outcome data from the Owen 1990 study was not pooled with
the data from Rahlfs 1976 and Rahlfs 1979 because of heterogene-
ity between the studies. The three studies investigated two differ-
ent types of homeopathy. For the same reason outcome data from
Peckham 2014 was not pooled with outcome data from Rahlfs
1976 and Rahlfs 1979. Owen 1990 and Peckham 2014 investi-
gated the effectiveness of individualised (classical) homeopathic
treatment, whilst Rahlfs 1976 and Rahlfs 1979 investigated clini-
cal homeopathy. The type of IBS investigated was also potentially
different. In the Owen 1990 and Peckham 2014 studies partic-
ipants were diagnosed with IBS and no further information on
type was given, whilst the participants in Rahlfs 1976 and Rahlfs
1979 had constipation-predominant IBS. In addition, the stud-
ies measured outcomes at different time points. Peckham 2014
measured outcomes at 26 weeks and Owen 1990 measured out-
comes at 12 weeks, whilst Rahlfs 1976 and Rahlfs 1979 measured
outcomes at 2 weeks. The primary outcome for the Owen 1990
study was not a global improvement measure and was not com-
parable with the other three studies. Although it may be tempting
to combine studies in a meta-analysis when it is likely to yield a
statistically significant result, it is important not to combine stud-
ies where there is significant clinical heterogeneity, because these
results would not be meaningful due to the large degree of differ-
ences between the studies. For these reasons the outcomes from
Owen 1990, Peckham 2014, Rahlfs 1976 and Rahlfs 1979 were
not combined.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Homeopathy versus usual care for the treatment of irritable bowel syndrome
Patient or population: pat ients with irritable bowel syndrome
Settings: outpat ients
Intervention: homeopathy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Usual care Homeopathy
Global improvement
(Feeling unwell)
Follow-up: 12 weeks
The mean global im-
provement score was 1.
41 (SD = 1.97)
The mean global im-
provement score was 1.
44 (SD = 4.55)
MD 0.03 higher (3.16
lower to 3.22 higher)
- 20
(1 study)
⊕©©©
very low1,2
Global improvement de-
f ined as a self reported
improvement of symp-
toms. Scale f rom: 0 to
5
Higher scores indicate
greater improvement
Quality of life Not reported This outcome was not
reported
Abdominal pain Not reported This outcome was not
reported
Stool frequency Not reported This outcome was not
reported
Stool consistency Not reported This outcome was not
reported
Adverse events Not reported This outcome was not
reported
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* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded one level due to high risk of bias
2 Downgraded two levels due to very sparse data (20 part icipants)
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Homeopathy plus usual care versus usual care for the treatment of irritable bowel syndrome
Patient or population: pat ients with irritable bowel syndrome
Settings: outpat ients
Intervention: homeopathy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Homeopathy
Global improvement
(IBS-SSS)
Follow-up: 6 months
The mean global im-
provement score was
237.3 (SD = 110.27)
The mean global im-
provement score was
210.44 (SD = 112.4)
MD 26.86 lower (88.59
lower to 34.87 higher)
- 76
(1 study)
⊕⊕©©
low1,2
IBS-SSS. Scale f rom: 0
to 400
Lower scores indicate
less severe disease
Quality of life
Follow-up 6 months
The mean quality of lif e
score was 63.41 (SD =
23.31)
The mean quality of lif e
score was 69.07 (SD =
17.35)
MD 5.66 higher (4.69
lower to 16.01 higher)
- 76
(1 study)
⊕⊕©©
low1,2
EQ-5D
Higher scores indicate
better quality of lif e
Abdominal pain Not reported This outcome was not
reported
Stool frequency Not reported This outcome was not
reported
Stool consistency Not reported This outcome was not
reported
Adverse events Not reported This outcome was not
reported
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* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded one level due to sparse data (76 part icipants)
2 Downgraded one level due to high risk of bias
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Homeopathy plus usual care versus support ive listening plus usual care for treatment of irritable bowel syndrome
Patient or population: pat ients with irritable bowel syndrome
Settings: outpat ients
Intervention: Homeopathy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Homeopathy
Global improvement
(IBS-SSS)
Follow-up: 6 months
The mean global im-
provement score was
262 (SD = 120.72)
The mean global im-
provement score was
210.44 (SD = 112.4)
MD 51.56 lower (129.94
lower to 26.82 higher)
- 34
(1 study)
⊕©©©
very low1,2
IBS-SSS. Scale f rom: 0
to 400
Lower scores indicate
less severe disease
Quality of life
Follow-up: 6 months
The mean quality of lif e
score was 63.09 (SD =
24.38)
The mean quality of lif e
score was 69.07 (SD =
17.35)
MD 5.98 higher (8.13
lower to 20.09 higher)
- 34
(1 study)
⊕©©©
very low1,2
EQ-5D
Higher scores indicate
better quality of lif e
Quality of life Not reported This outcome was not
reported
Abdominal pain Not reported This outcome was not
reported
Stool frequency Not reported This outcome was not
reported
Stool consistency Not reported This outcome was not
reported
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Adverse events Not reported This outcome was not
reported
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Downgraded two levels due to very sparse data (34 part icipants)
2 Downgraded one level due to high risk of bias
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D I S C U S S I O N
Summary of main results
Two RCTs compared a clinical homeopathic remedy (asafoetida
and asafoetida plus nux vomica) with placebo for treating IBS-C
(Rahlfs 1976; Rahlfs 1979). In a meta-analysis of these studies,
the homeopathic remedy found that there may be a benefit of the
remedy over placebo for improvement in global IBS symptoms at
a short-term follow-up of two weeks. However, this result should
be interpreted with caution due to the low quality of the reporting
in these studies, a high or unknown risk of bias associated with
the trials in this pooled analysis, short-term follow-up, and sparse
data.
Two RCTs (Owen 1990; Peckham 2014) compared individualised
homeopathic treatment with usual care. In Owen 1990 individ-
ualised homeopathic treatment was compared to usual care (di-
cyclomine hydrochloride, faecal bulking agents, and diet sheets
advising a high fibre diet). No conclusions can be drawn from this
study due to the small number of participants, the low quality of
reporting in this trial and a high risk of bias. Although Peckham
2014 has a low risk of bias and the quality of the reporting is good
it is difficult to draw conclusions from this study due to the small
number of participants.
Overall completeness and applicability of
evidence
Rahlfs 1976 and Rahlfs 1979 assessed the effectiveness of clinical
homeopathy for the treatment of constipation-predominant IBS.
Therefore this review does not provide information on the effec-
tiveness of clinical homeopathy for the treatment of IBS in general,
or diarrhoea-predominant, or mixed typology IBS. Both Rahlfs
1976 and Rahlfs 1979 reported outcomes at two weeks. Given
the long term nature of IBS it is not clear how useful a two-week
outcome is for patients’, clinicians’ and policy makers’ decision
making. As people live with IBS for years, an evaluation of impact
at two weeks fails to take into account possible rebound effects or
longer term benefits or adverse events that would be important for
patients and practitioners to know about when they consider the
potential benefits and harms associated with this intervention.
Two studies that assessed the effectiveness of individualised home-
opathic treatment were identified in this review (Owen 1990;
Peckham 2014). The number of participants in both these stud-
ies were small (N = 23 and N = 94 respectively). Owen 1990
was conducted over 25 years ago. It is likely that there have been
changes in usual care for IBS since this time, therefore Owen 1990
may not provide a full picture of the effectiveness of individualised
homeopathic treatment compared to usual care. Peckham 2014
was conducted more recently and is likely to compare individu-
alised homeopathic treatment to current usual care however given
the small size of this study and the fact that it is underpowered
makes it difficult to draw any firm conclusions from the study.
Quality of the evidence
The results from the pooled analysis indicate a possible benefit for
homeopathic treatment using clinical homeopathy (non-individ-
ualised homeopathic remedies) over placebo for constipation-pre-
dominant IBS. However, this result needs to be interpreted with
caution. The two studies included in the pooled analysis (Rahlfs
1976 and Rahlfs 1979) were carried out in the 1970s before the
introduction of the CONSORT statement (Begg 1996), and the
quality of reporting in these studies does not meet currently ex-
pected standards (Schultz 2010). The low quality of the reporting
means that it is not possible to determine whether or not these
studies were carried out in a rigorous manner and thus how likely
it is that these results are a true reflection of the treatment effect.
Both studies were determined to have an unknown risk of bias for
most assessed items and Rahlfs 1979 was at a high risk of reporting
bias. The quality of the evidence supporting the primary outcome
(i.e. global improvement) was very low due to the low quality of
reporting in the included studies, high or unknown risk of bias,
sparse data and short-term follow-up.
Participants in the Rahlfs 1976 and Rahlfs 1979 studies were re-
cruited through general practice as having suspected IBS. It is not
clear whether diseases such as Crohn’s disease or ulcerative colitis
were ruled out in these participants and it is possible that some
participants had diseases such as Crohn’s or ulcerative colitis rather
than IBS.
The quality of the reporting in the Owen 1990 study was low, and
this study does not meet the current expected standards (Schultz
2010). No conclusions can be drawn from this study due to the
small number of participants and risk of bias. Owen 1990 was
rated as high risk of bias for blinding of participants and personnel.
The study was rated as unknown risk of bias for the other assessed
items. The exact details of the medication prescribed in the usual
care arm, in terms of dosage and frequency were not reported.
The quality of the reporting in the Peckham 2014 was good and
combined with the published protocol it meets the current ex-
pected standards (Schultz 2010). Peckham 2014 was rated as being
at low risk of bias for selection bias, attrition bias and reporting
bias and at high risk of bias for performance bias and detection
bias. However the small number of participants in this study (n =
16 homeopathic treatment, n = 18 supportive listening and n =
60 usual care) and the fact that it was underpowered mean no firm
conclusions can be drawn from this study. The quality of the evi-
dence supporting the primary outcome (i.e. global improvement)
ranged from very low to low due to sparse data and high risk of
bias.
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Potential biases in the review process
To avoid potential biases in the review process data extraction was
carried out independently by two assessors. In addition, efforts
were made to identify all studies that were potentially eligible
for this review (see Search methods for identification of studies).
However, It is possible that not all potentially eligible studies were
identified. This could be because potentially eligible studies have
been carried out and then have not been published, or that studies
have been published but not in places where they could be accessed,
possibly because they were published in little known non-indexed
journals or they could have been published in places where they
should have been found, but were not found. One of the review
authors (EJP) was a trialist for an included study (Peckham 2014).
For this study, the assessment of risk of bias and data extraction was
performed by other authors. Cohort and case-control studies were
considered for inclusion but none were identified by the literature
search. In retrospect the inclusion of case-control studies was not
appropriate given that the main reason for including case-control
studies in a review is when an event is very rare and thus it is
unlikely that any RCTs have been carried out (Reeves 2011).
Agreements and disagreements with other
studies or reviews
No other systematic reviews of homeopathic treatment for IBS
were identified. However non-condition specific systematic re-
views of homeopathic treatment that included the Rahlfs 1976
and Rahlfs 1979 studies have been published (Linde 1997; Shang
2005). Neither of these systematic reviews carried out any analy-
ses on homeopathy for the treatment of IBS or specifically com-
mented on homeopathy for IBS.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The results for the outcomes assessed in this review are uncertain.
Thus no firm conclusions regarding the effectiveness and safety of
homeopathy for the treatment of IBS can be drawn.
In this review of homeopathic treatment for IBS, two of the
included studies used clinical (non-individualised) homeopathic
remedies to treat patients with constipation-predominant IBS
(Rahlfs 1976; Rahlfs 1979). A meta-analysis of these two studies
found a possible benefit favouring the homeopathic remedy over
placebo. However, these results should be interpreted with cau-
tion due to the low quality of reporting in these studies, a high
or unknown risk of bias and sparse data. Thus it is not possible
to be certain whether or not the trials were able to distinguish
between true treatment effects, chance or bias. Furthermore, the
low quality of reporting practice means that it is difficult to assess
whether the results would be replicated in everyday practice, that
is, whether the results are externally valid or generalisable. We are
therefore very uncertain about these results and cannot suggest a
possible benefit for clinical homeopathy.
It is of note that Rahlfs 1976 and Rahlfs 1979 reported outcomes
at two weeks. Given the long term nature of IBS, it is not clear how
useful a two-week outcome is for decision making. It is essential
that trials have a follow-up period that is clinically meaningful.
As people live with IBS for years, an evaluation of impact at two
weeks fails to take into account any possible rebound effects, or
longer term benefits or adverse events that would be important for
patients and practitioners to know about when they consider the
potential benefits and harms associated with this intervention.
The results from Owen 1990 are uncertain and no conclusions
can be drawn from this study. Owen 1990 compared individu-
alised homeopathic treatment and usual care consisting of dicy-
clomine hydrochloride and faecal bulking agents. The results from
Peckham 2014 are uncertain and no conclusions can be drawn
from this study. Peckham 2014 compared individualised homeo-
pathic treatment plus usual care, supportive listening plus usual
care and usual care. Individualised homeopathy is the most com-
mon form of homeopathy practised in the UK. However due to
the poor quality of reporting in Owen 1990 study and the small
number of participants in both Owen 1990 and Peckham 2014,
no conclusions can be made regarding the usefulness of individu-
alised homeopathic treatment for the treatment of IBS.
None of the included studies reported on adverse events therefore
no conclusions can be drawn on the safety of homeopathic treat-
ment for IBS.
Implications for research
Further high quality, adequately powered RCTs are required to
assess the efficacy and safety of clinical and individualised home-
opathy for IBS compared to placebo or usual care.
Rahlfs 1976 and Rahlfs 1979 evaluated clinical homeopathy in-
volving pre-specified homeopathic remedies for the treatment of
IBS-C and were therefore designed to assess the effectiveness of
non-individualised homeopathic remedies. However due to the
high risk of reporting bias in one of these studies and unclear re-
porting in both of these studies it is recommended that these tri-
als are repeated using current reporting guidelines (Schultz 2010),
to determine whether or not there is any benefit associated with
homeopathy for IBS. Future high quality studies should enrol
larger numbers of patients and assess longer term efficacy and sa-
fety outcomes.
Owen 1990 assessed the effectiveness of individualised homeo-
pathic treatment compared to usual care and Peckham 2014 as-
sessed the effectiveness of individualised homeopathic treatment
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plus usual care to usual care. Due to the low quality reporting in
Owen 1990 and the likelihood that usual care for IBS has changed
since this study was conducted, and the fact that Peckham 2014
was underpowered to detect a significant difference, it is recom-
mended that the effectiveness and safety of individualised homeo-
pathic treatment be evaluated in a well-designed, adequately pow-
ered trial.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Owen 1990
Methods RCT, unblinded, parallel study, 12 weeks duration
Participants Setting; county hospital, UK
Number of participants; 23 patients were allocated into one of the treatment groups, 20
patients included in analysis
Recruitment methods; female patients attending the out-patient department at a county
hospital in whom a diagnosis of IBS was made
Diagnosis of IBS; clinical diagnosis by a consultant gastroenterologist and consultant
gynaecologist
Age range of patients; 20-69 years
Gender (of treated patients); 100% female
Duration of symptoms > 3 months
Interventions 1. Individualised homeopathic treatment
2. High doses of Dicyclomine hydrocholoride (exact dose not stated), faecal bulking
agents and diet sheets advising a high fibre diet
Outcomes Patients were asked to grade: their four worst symptoms on a visual analogue scale,
dysmenorrhoea, dyspareunia, and feeling unwell at baseline, 2, 6 and 12 weeks
Notes Detailed information is given on the homeopathic treatment the participants received
in terms of; remedy chosen, potency and dosage, whilst no information is given on
the strength and dosage of the dicyclomine hydrocholoride and faecal bulking agents
prescribed in the usual care arm
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Although it is stated that this is a ran-
domised trial no details were given as to
how randomisation was achieved
Allocation concealment (selection bias) Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient reporting of attrition, whilst
possible reasons for attrition were discussed
for one patient, the reasons for the other
two patients leaving the study were not re-
ported
Selective reporting (reporting bias) Unclear risk Insufficient information is provided to be
able to judge whether the study is at risk
from selective reporting
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Owen 1990 (Continued)
Other bias Unclear risk Due to the low quality of the reporting in
this study it is unclear whether the study is
at risk from any other forms of bias
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and doctors were not blinded
to allocation, however it is not stated
whether other key study personnel were
blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is not reported whether or not the out-
come assessment was carried out blind
Peckham 2014
Methods Three arm, parallel group non-blinded randomised controlled trial 26 weeks in duration
Participants Setting: Hospital outpatient, UK
Number of participants; 94 patients were allocated into one of the treatment groups
in a 4:1:1 ratio, 60 patients were allocated to usual care, 16 were offered homeopathic
treatment plus usual care and 18 were offered supportive listening plus usual care
Recruitment methods; GP database recruitment, consultant gastroenterologist in sec-
ondary care
Diagnosis of IBS; diagnosed according to the Rome III criteria, potentially eligible
participants were asked to complete a questionnaire which included the Rome III criteria
for IBS. Participants had to score a minimum of 100 on the IBS-SSS to be eligible to
take part in the trial
Mean age range of participants; 49 years
Gender; 83% female
Duration of symptoms > 3 months
Interventions 1. Individualised homeopathic treatment plus usual care
2. Supportive listening plus usual care
3. Usual care
Outcomes IBS-SSS, EQ-5D, HADS
Notes This study employed a Trials Within Cohorts design which recruited a cohort of people
with IBS. From this cohort people were randomly selected to receive the offer of a
treatment
Risk of bias
Bias Authors’ judgement Support for judgement
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Peckham 2014 (Continued)
Random sequence generation (selection
bias)
Low risk Random sequence generated by shuffling
of sealed opaque envelopes containing the
allocation (protocol paper)
Allocation concealment (selection bias) Low risk Questionnaires from participants consent-
ing and meeting the eligibility criteria are
taken one at a time, at the same time a sealed
opaque envelope containing the allocation
is taken from the top of the shuffled pack
and opened and the allocation noted. This
is carried out by an independent adminis-
trator at the University of Sheffield, in the
presence of another independent adminis-
trator. (protocol paper)
Incomplete outcome data (attrition bias)
All outcomes
Low risk The proportion of patients who dropped
out of the usual care and supportive listen-
ing arms was similar and the reasons for
dropping out were the same in both groups
9/60 (15%) participants in the usual care
arm did not return the follow-up question-
naire
All 16 participants in the homeopathy arm
were included in the analysis
3/18 (17%) participants in the supportive
listening arm did not return the question-
naire
Selective reporting (reporting bias) Low risk Outcome data presented for those outcome
measures stated in the protocol
Other bias Low risk The quality of reporting in this study was
good and did not indicate that there were
likely to be other forms of bias
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Neither the nature of the interventions in
this study nor the study design allows for
the masking of the therapists or the partic-
ipants
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcomes were patient-reported outcomes
(i.e. the patient was the outcome assessor)
. As the patients were aware of the group
allocation, this domain was judged as high
risk of bias
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Rahlfs 1976
Methods RCT, double blind, parallel study, 2 weeks duration
Participants Setting; general practice, Germany
Number of participants; 71 patients treated (number of patients randomised not clearly
stated), 63 patients included in analysis
Recruitment methods; patients presenting in general practice with suspected IBS
Diagnosis of IBS; Clinical diagnosis plus completion of detailed questionnaire
Mean age (of treated patients); 43.8 years
Gender (of treated patients); 50.8% female
Duration of symptoms > 14 days
Interventions 1. 0.1% asafoetida alcohol solution, 6 x 5 drops daily
2. 0.1% asafoetida alcohol solution + 0.01% nux vomica alcohol solution, 6 x 5 drops
daily
3. placebo, 45% alcohol solution, 6 x 5 drops daily
Outcomes Self assessment on a 3 point scale; no or negligible improvement, more than half im-
proved, free of symptoms measured on day 8 and day 15 of the study
Time to recovery assessed by the patient reporting the day they felt considerable im-
provement
Freiburg Personality Inventory
Notes Analysed participant data were fairly well described, but a lot of pre-randomisation and
pre-analysis data were missing
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk A chance code was used for the randomi-
sation, the exact nature of which was not
reported
Therefore the risk of bias cannot be deter-
mined
Allocation concealment (selection bias) Low risk Medication was provided in sequentially
numbered drug containers
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient reporting of attrition, some
reasons for attrition are given, details of al-
location are not always given
Selective reporting (reporting bias) Unclear risk Insufficient information was provided to be
able to judge whether the study was at risk
from selective reporting
Other bias Unclear risk Insufficient information was provided to
assess whether the study was at risk from
any other bias
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Rahlfs 1976 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study participants and recruiting doctors
were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It was not reported whether outcome as-
sessment was carried out blind
Rahlfs 1979
Methods RCT, double blind, parallel study, 2 weeks duration
Participants Setting; general practice, Germany
Number of participants; 119 patients treated (number of participants randomised not
clearly stated), 89 patients included in analysis
Recruitment methods; patients presenting in general practice with suspected IBS
Diagnosis of IBS; Clinical diagnosis plus completion of detailed questionnaire
Mean age (of patients included in analysis, ages of those not included not stated); 42.5
years
Gender (of those included in analysis, gender of those not included not stated); 68.5%
female
Duration of symptoms > 14 days
Interventions 1. 0.1% asafoetida alcohol solution, 6 x 5 drops daily
2. placebo, 45% alcohol solution, 6 x 5 drops daily
Outcomes Self assessment on a 4 point scale; worsening of symptoms, no or negligible improvement,
more than half improved, free of symptoms, measured on day 8 and day 15 of the study
Time to recovery assessed by the patient reporting the day they felt considerable im-
provement
Notes Analysed participant data were fairly well described, but a lot of pre-randomisation and
pre-analysis data were missing
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Although it was reported that this was a
randomised trial no details were given as to
how randomisation was achieved
Allocation concealment (selection bias) Low risk Medication was provided in sequentially
numbered drug containers
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Incomplete outcome data, reasons for miss-
ing data, and how incomplete outcome
data were addressed was not clearly de-
31Homeopathy for treatment of irritable bowel syndrome (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Rahlfs 1979 (Continued)
scribed
Selective reporting (reporting bias) High risk The inclusion and exclusion criteria were
applied in a variable manner, some people
that were subsequently found not to meet
the exclusion and inclusion criteria were re-
moved from the analysis
However people who did not meet the in-
clusion criteria for age, being too old were
still included in the analysis
This leaves the study at risk of bias due to
selective reporting
Other bias Unclear risk Due to the low quality of the reporting it
was unclear whether the study was at risk
from any other forms of bias
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and doctors were blinded to
allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It was not reported whether outcome as-
sessment was carried out blind to treatment
allocation
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aleem 2000 Discussion piece and not a randomised controlled trial, cohort or case-control study
Anonymous 2005 An initial reading of this Italian article revealed it to be discussing a meta analysis by Shang 2005
Therefore a full translation was not conducted
Anonymous 2009 Discussion piece and not a randomised controlled trial, cohort or case-control study
Bauer 2014 Case studies on the treatment of IBS and not a randomised controlled trial, cohort or case-control study
Bhagat 2010 Case report (n = 1) of homeopathic treatment for IBS
Bhattacharjee 2010 The article was a discussion on the different homeopathic remedies used for the treatment of IBS
Chen 2015 A discussion on the use of complementary therapies for the treatment of functional gastrointestinal disorders
Cherniack 2013 Not on IBS
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(Continued)
Chimthanawala 2004 Case report (n = 2) of homeopathic treatment for IBS
Diamond 2005 A discussion on the use of complementary therapies for the treatment of gastroenterological problems
Elio 2014 Report on a series of patients attending a clinic. Not specific to IBS and not an RCT or case series
Feldhaus 2000 This was a discussion piece on the treatment of IBS
Gamble 2007 Discussion of a potentially new way of assessing and treating IBS, from a homeopathic perspective, using
two cases as an example
Gebhardt 1988 Discussion on homeopathic treatment for IBS, not a randomised controlled trial, cohort or case-control
study
Gray 1998 This study was a case series of 25 patients with no comparator group
Greeson 2008 Non-randomised observational study of outcomes for patients attending a integrative medical centre where
homeopathy was only one of the treatments offered
Grundmann 2014 Review of treatments for IBS does not include homeopathy
Innes 2000 This study was a case series (n = 20) with no comparator group
Jagose 2004 Case report (n = 1) of homeopathic treatment for IBS
Jones 1996 A discussion of the homeopathic treatment of IBS, illustrated by three cases
Jones 1997 Discussion piece on homeopathic treatment of IBS
Jones 1999 Case report study of a woman with IBS treated with homeopathy
Krishendu 2010 A discussion of the different homeopathic remedies used for the treatment of IBS
Lobo 2000 Case report (n = 1) on homeopathic treatment of IBS
Master 2008 Discussion piece on homeopathy for IBS
Mohan 2006 Case report (n = 2) of IBS treated with homeopathy
Pawar 2015 A discussion on homeopathic remedies
Pinto 1999 A selection of case reports on homeopathic treatment for a variety of conditions
Pohl 2013 An overview of treatments for irritable bowel syndrome which does not include homeopathy
Slade 2003 Case report (n = 1) of homeopathic treatment of ulcerative colitis
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(Continued)
Turner 2008 Discussion of homeopathic treatment of IBS, illustrated by eight case histories
White 1999 Discussion of homeopathic treatment for IBS, not a randomised controlled trial, cohort or case-control study
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D A T A A N D A N A L Y S E S
Comparison 1. Homeopathy versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Homeopathy versus placebo 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Global improvement
(Asafoetida only)
2 129 Risk Ratio (M-H, Fixed, 95% CI) 1.61 [1.18, 2.18]
1.2 Global improvement
(Asafoetida + nux vom)
1 42 Risk Ratio (M-H, Fixed, 95% CI) 1.31 [0.80, 2.15]
Comparison 2. Homeopathy versus usual care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Global improvement (feeling
unwell)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 3. Homeopathy plus usual care versus usual care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Global improvement (IBS-SSS) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Quality of life 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 4. Homeopathy plus usual care versus supportive listening plus usual care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Global improvement (IBS-SSS) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Quality of life 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
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Analysis 1.1. Comparison 1 Homeopathy versus placebo, Outcome 1 Homeopathy versus placebo.
Review: Homeopathy for treatment of irritable bowel syndrome
Comparison: 1 Homeopathy versus placebo
Outcome: 1 Homeopathy versus placebo
Study or subgroup Homeopathy Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Global improvement (Asafoetida only)
Rahlfs 1976 14/21 12/23 39.2 % 1.28 [ 0.78, 2.10 ]
Rahlfs 1979 32/42 18/43 60.8 % 1.82 [ 1.23, 2.69 ]
Subtotal (95% CI) 63 66 100.0 % 1.61 [ 1.18, 2.18 ]
Total events: 46 (Homeopathy), 30 (Placebo)
Heterogeneity: Chi2 = 1.22, df = 1 (P = 0.27); I2 =18%
Test for overall effect: Z = 3.04 (P = 0.0024)
2 Global improvement (Asafoetida + nux vom)
Rahlfs 1976 13/19 12/23 100.0 % 1.31 [ 0.80, 2.15 ]
Subtotal (95% CI) 19 23 100.0 % 1.31 [ 0.80, 2.15 ]
Total events: 13 (Homeopathy), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
Test for subgroup differences: Chi2 = 0.47, df = 1 (P = 0.49), I2 =0.0%
0.01 0.1 1 10 100
Favours placebo Favours homeopathy
36Homeopathy for treatment of irritable bowel syndrome (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.1. Comparison 2 Homeopathy versus usual care, Outcome 1 Global improvement (feeling
unwell).
Review: Homeopathy for treatment of irritable bowel syndrome
Comparison: 2 Homeopathy versus usual care
Outcome: 1 Global improvement (feeling unwell)
Study or subgroup Homeopathy Usual care
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Owen 1990 9 1.44 (4.55) 11 1.41 (1.97) 0.03 [ -3.16, 3.22 ]
-4 -2 0 2 4
Favours usual care Favours homeopathy
Analysis 3.1. Comparison 3 Homeopathy plus usual care versus usual care, Outcome 1 Global improvement
(IBS-SSS).
Review: Homeopathy for treatment of irritable bowel syndrome
Comparison: 3 Homeopathy plus usual care versus usual care
Outcome: 1 Global improvement (IBS-SSS)
Study or subgroup Homeopathy Usual care
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Peckham 2014 16 210.44 (112.4) 60 237.3 (110.22) -26.86 [ -88.59, 34.87 ]
-100 -50 0 50 100
Favours homeopathy Favours usual care
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Analysis 3.2. Comparison 3 Homeopathy plus usual care versus usual care, Outcome 2 Quality of life.
Review: Homeopathy for treatment of irritable bowel syndrome
Comparison: 3 Homeopathy plus usual care versus usual care
Outcome: 2 Quality of life
Study or subgroup Homeopathy Usual care
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Peckham 2014 16 69.07 (17.35) 60 63.41 (23.31) 5.66 [ -4.69, 16.01 ]
-100 -50 0 50 100
Favours usual care Favours homeopathy
Analysis 4.1. Comparison 4 Homeopathy plus usual care versus supportive listening plus usual care,
Outcome 1 Global improvement (IBS-SSS).
Review: Homeopathy for treatment of irritable bowel syndrome
Comparison: 4 Homeopathy plus usual care versus supportive listening plus usual care
Outcome: 1 Global improvement (IBS-SSS)
Study or subgroup Homeopathy Supportive listening
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Peckham 2014 16 210.44 (112.4) 18 262 (120.72) -51.56 [ -129.94, 26.82 ]
-100 -50 0 50 100
Favours homeopathy Favours control
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Analysis 4.2. Comparison 4 Homeopathy plus usual care versus supportive listening plus usual care,
Outcome 2 Quality of life.
Review: Homeopathy for treatment of irritable bowel syndrome
Comparison: 4 Homeopathy plus usual care versus supportive listening plus usual care
Outcome: 2 Quality of life
Study or subgroup Homeopathy Supportive listening
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Peckham 2014 16 69.07 (17.35) 18 63.09 (24.38) 5.98 [ -8.13, 20.09 ]
-100 -50 0 50 100
Favours control Favours homeopathy
A P P E N D I C E S
Appendix 1. Search Strategies
Medline
1. Colonic disease*.mp
2. irritable bowel syndrome/
3. colonic diseases, functional/
4. irritable bowel/
5. irritable colon/
6. spastic colon/
7. functional bowel disease*.mp.
8. functional colonic disease*.mp.
9. or/1-8
10. homeopathy/
11. homeopath*.mp.
12. homoeopath*.mp.
13. alternative medicine*.mp.
14. or/10-13
15. 9 and 14
EMBASE
1. Colonic disease*.mp
2. irritable bowel syndrome/
3. colonic diseases, functional/
4. irritable bowel/
5. irritable colon/
6. spastic colon/
7. functional bowel disease*.mp.
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8. functional colonic disease*.mp.
9. or/1-8
10. homeopathy/
11. homeopath*.mp.
12. homoeopath*.mp.
13. alternative medicine*.mp.
14. or/10-13
15. 9 and 14
CENTRAL
#1 MeSH: [Irritable bowel syndrome] explode all trees
#2 Colonic disease*
#3 irritable bowel syndrome
#4 colonic diseases, functional
#5 irritable bowel
#6 irritable colon
#7 spastic colon
#8 functional bowel disease*
#9 functional colonic disease*
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
#11 homeopathy
#12 homeopath*
#13 homoeopath*
#14 alternative medicine*
#15 #11 or #12 or #13 or #14
#16 #10 and #15
Cumulative Index to Nursing and Allied Health Literature (CINAHL)
1. (TI homeopathy or AB homeopathy) OR (TI homeopath* or AB homeopath*) OR (TI homoeopath* or AB homoeopath*) OR
(TI alternative medicine* of AB alternative medicine*)
2. (TI Irritable bowel syndrome or AB Irritable bowel syndrome) OR (TI Colonic disease* or AB Colonic disease*) OR (TI irritable
colon or AB irritable colon) OR (TI spastic colon or AB spastic colon) OR (TI functional bowel disease* or AB functional bowel
disease*) OR (TI functional colonic disease* or AB functional colonic disease*)
Allied and Complementary Medicine Database (AMED)
1. Colonic disease*.mp
2. irritable bowel syndrome/
3. colonic diseases, functional/
4. irritable bowel/
5. irritable colon/
6. spastic colon/
7. functional bowel disease*.mp.
8. functional colonic disease*.mp.
9. or/1-8
10. homeopathy/
11. homeopath*.mp.
12. homoeopath*.mp.
13. alternative medicine*.mp.
14. or/10-13
15. 9 and 14
Clinical trials. Gov
1. Homeopathy and Irritable bowel syndrome
IBD specialized register
1. Irritable bowel syndrome and homeopath
2. Colonic diseases and homeopath
3. Functional bowel and homeopath
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W H A T ’ S N E W
Date Event Description
31 August 2018 New search has been performed New search and one new study added
31 August 2018 New citation required but conclusions have not changed Updated review, no new conclusions
C O N T R I B U T I O N S O F A U T H O R S
EJP initiated, designed the study and drafted the protocol. EP, SB and GT, extracted the data and conducted the quality assessment.
AA and KC arbitrated. KC provided advice on meta analysis. KC, SB, GT and AA all commented on the review.
D E C L A R A T I O N S O F I N T E R E S T
EJP has contributed to the design and management of one of the included RCTs. EJP is a homeopath.
GT: None known.
SB: None known.
KC: None known.
AA: None known.
S O U R C E S O F S U P P O R T
Internal sources
• University of Leeds, UK.
• Homeopathy Research Institute, UK.
• ScHARR, UK.
External sources
• No sources of support supplied
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Ferula; Constipation [therapy]; Dicyclomine [therapeutic use]; Dietary Fiber [therapeutic use]; Homeopathy [∗methods]; Irritable
Bowel Syndrome [∗therapy]; Phytotherapy [methods]; Randomized Controlled Trials as Topic
MeSH check words
Adult; Female; Humans; Male
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